Regenerative Medicine Trust
Reported revenue in 2021 ¥391.21M Reported revenue in 2025 ¥546.37M
- growth amount
- +¥155.16M
- growth annualized
- +8.7%
- growth total
- +39.7%
Japanese company profile · 7774
Japan Tissue Engineering Co., Ltd.
In its FY2025 public filing, Japan Tissue Engineering Co., Ltd. reports Regenerative medicine, Regenerative Medicine Trust, Labsite. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: 株式会社ジャパン・ティッシュエンジニアリング
English company name recorded in Japan's EDINET filer data. English company name source
What does this company do?
What does this company do?
Japan Tissue Engineering Co., Ltd.'s largest reported business by revenue in FY2025 was Regenerative medicine.
The business with the highest reported segment profit in FY2025 was Regenerative Medicine Trust.
FY2025 · fiscal year ended March 2026 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Sales | Revenue share | Operating profit |
|---|---|---|---|
| Regenerative medicine | ¥1.35B ↗ | — | ¥78.3M ↗ |
| Regenerative Medicine Trust | ¥546.37M ↗ | — | ¥327.44M ↗ |
| Labsite | ¥281.88M ↗ | — | ¥52.77M ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Regenerative medicine
- 再生医療製品事業
- Regenerative Medicine Trust
- 再生医療受託事業
- Labsite
- ラボサイト事業
- Business label unavailable in English
- 研究開発支援事業
- Sales
- 売上高
- Operating profit
- 営業利益
Original Japanese label
- Regenerative medicine
- 再生医療製品事業
- Regenerative Medicine Trust
- 再生医療受託事業
- Labsite
- ラボサイト事業
- Business label unavailable in English
- 研究開発支援事業
- Sales
- 売上高
- Operating profit
- 営業利益
What is growing?
What is growing?
Business revenue growth
Labsite
Reported revenue in 2022 ¥206.9M Reported revenue in 2025 ¥281.88M
- growth amount
- +¥74.98M
- growth annualized
- +10.9%
- growth total
- +36.2%
View original filing
Regenerative Medicine Trust
Reported profit margin in 2022 +37.6%
Reported profit margin in 2025 +59.9%
- growth margin points
- +22.3
View original filing
Business label unavailable in English
Reported profit margin in 2021 +10.9%
Reported profit margin in 2024 +27.2%
- growth margin points
- +16.3
View original filing
Regenerative medicine
Reported profit margin in 2022 +2.8%
Reported profit margin in 2025 +5.8%
- growth margin points
- +2.9
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2025 · fiscal year ended March 2026
The source document may be in Japanese.
Filing ID: S100YDBW
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.